Celldex Therapeutics IncFind Ratings Reports
CELLDEX THERAPEUTICS INC's gross profit margin for the first quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. CELLDEX THERAPEUTICS INC is extremely liquid. Currently, the Quick Ratio is 6.23 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
During the same period, stockholders' equity ("net worth") has remained virtually unchanged only decreasing by 4.69% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY17||Q1 FY16|
|Net Sales ($mil)||1.53||1.3|
|Net Income ($mil)||-34.26||-34.67|
|Balance Sheet||Q1 FY17||Q1 FY16|
|Cash & Equiv. ($mil)||167.02||254.02|
|Total Assets ($mil)||360.05||301.93|
|Total Debt ($mil)||0.0||0.0|
|Profitability||Q1 FY17||Q1 FY16|
|Gross Profit Margin||-1963.62||-2663.78|
|Return on Assets||-35.58||-43.61|
|Return on Equity||-51.69||-50.64|
|Debt||Q1 FY17||Q1 FY16|
|Share Data||Q1 FY17||Q1 FY16|
|Shares outstanding (mil)||124.17||98.72|
|Div / share||0.0||0.0|
|Book value / share||2.0||2.63|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||2030697.0||1914997.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 1.29 indicates a significant discount versus the S&P 500 average of 3.09 and a significant discount versus the industry average of 11.09. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, CELLDEX THERAPEUTICS INC proves to trade at a discount to investment alternatives within the industry.
|CLDX NM||Peers 41.96||CLDX NM||Peers 43.61|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
CLDX's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
CLDX's P/CF is negative making the measure meaningless.
|CLDX NM||Peers 26.44||CLDX NA||Peers 0.54|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
CLDX's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|CLDX 1.29||Peers 11.09||CLDX 10.53||Peers -9.68|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
CLDX is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
CLDX is expected to have an earnings growth rate that significantly exceeds its peers.
|CLDX 45.64||Peers 172.46||CLDX 11.43||Peers 462.34|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
CLDX is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
CLDX significantly trails its peers on the basis of sales growth